Drug Search Results
More Filters [+]

Mitoguazone

Alternative Names: mitoguazone
Latest Update: 2024-05-01
Latest Update Note: PubMed Publication

Product Description

Mechanisms of Action: No Mechanism

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Sanofi
Company Location: PARIS I0 75008
Company CEO: Paul Hudson
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Mitoguazone

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: HIV Infections|Lymphoma, Non-Hodgkin|Acquired Immunodeficiency Syndrome

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

241A

P2

Completed

HIV Infections|Lymphoma, Non-Hodgkin|Acquired Immunodeficiency Syndrome

None

Recent News Events